






# Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

José L. Calleja<sup>1</sup>  | Jesús Rivera-Esteban<sup>2,3</sup>  | Rocío Aller<sup>4,5</sup> | Marta Hernández-Conde<sup>1</sup>  |  
 Javier Abad<sup>1</sup> | Juan M. Pericàs<sup>2</sup>  | Hugo G. Benito<sup>5</sup> | Miguel A. Serra<sup>6</sup> |  
 Amparo Escudero<sup>6</sup> | Javier Ampuero<sup>7</sup>  | Ana Lucena<sup>7</sup> | Yolanda Sánchez<sup>7</sup> |  
 María T. Arias-Loste<sup>8</sup>  | Paula Iruzubieta<sup>8</sup>  | Manuel Romero-Gómez<sup>7</sup>  |  
 Salvador Augustin<sup>2,3,9</sup>  | Javier Crespo<sup>8</sup> 

<sup>1</sup>Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, School of Medicine, Universidad Autónoma Madrid, IDIPHIM, Majadahonda, Spain

<sup>2</sup>Liver Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

<sup>3</sup>Universitat Autònoma de Barcelona, Bellaterra, Spain

<sup>4</sup>Department of Gastroenterology, Clinic University Hospital, Medical School, Group of Biomedical Research in Critical Care Medicine (BioCritic), University of Valladolid, Valladolid, Spain

<sup>5</sup>Research Unit, Clinic University Hospital, Medical School, Institute of Health Sciences of Castille and Leon (IECSCYL), Group of Biomedical Research in Critical Care Medicine (BioCritic), Valladolid, Spain

<sup>6</sup>Digestive Medicine Service, Clinic University Hospital, University of Valencia, Valencia, Spain

<sup>7</sup>Digestive Diseases Department and CIBERehd, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain

<sup>8</sup>Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Clinical and Translational Digestive Research Group, IDIVAL, Santander, Spain

<sup>9</sup>Therapeutic Area Cardio-Metabolism and Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

## Correspondence

Salvador Augustin, Therapeutic Area Cardio-Metabolism and Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

Email: [salva.augustin@gmail.com](mailto:salva.augustin@gmail.com); [salvador.augustin@boehringer-ingelheim.com](mailto:salvador.augustin@boehringer-ingelheim.com)

Jesús Rivera-Esteban, Liver Unit, Department of Internal Medicine, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus. Passeig Vall d'Hebron 119- 129, 08035 Barcelona, Spain. Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain. Email: [jesusriveraest@gmail.com](mailto:jesusriveraest@gmail.com)

## Abstract

**Background & Aims:** Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain.

**Methods:** This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large ( $N = 12\,246$ ) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres ( $N = 501$ ). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort.

**Abbreviations:** ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; CAP, controlled attenuation parameter; CI, confidence interval.; GGT, gamma-glutamyl transferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HDL, high-density lipoprotein; INE, Instituto Nacional Estadística; LDL, low-density lipoprotein; LSM, liver stiffness measurement; NAFLD, Non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NCEP-ATP III, National Cholesterol Education Program-Adult Treatment Panel III; TE, transient elastography.

José L. Calleja and Jesús Rivera-Esteban are co-first authors contributed equally to the manuscript

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Liver International* published by John Wiley & Sons Ltd.



Handling Editor: Dr. Luca Valenti

**Results:** From the patients with valid TE in ETHON dataset ( $N = 11440$ ), 5.61% (95% confidence interval [95% CI]: 2.53–11.97) had a liver stiffness measurement (LSM)  $\geq 8$  kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57.3% and thus, the estimated prevalence of population with LSM  $\geq 8$  kPa because of NAFLD was 3.21% (95% CI 1.13–8.75). In the biopsy-proven NASH cohort, 389 patients had LSM  $\geq 8$  kPa. Among these, 37% did not have significant fibrosis (F2–4). The estimated prevalence of NASH F2–3 and cirrhosis in Spain's adult population were 1.33% (95% CI 0.29–5.98) and 0.70% (95% CI 0.10–4.95) respectively.

**Conclusions:** These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available.

#### KEYWORDS

hepatic fibrosis, liver biopsy, non-alcoholic steatohepatitis, transient elastography

## 1 | INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem. Both its prevalence and incidence have risen sharply in the last decades.<sup>1–5</sup> and, by 2030, cirrhosis and hepatocellular carcinoma because of NAFLD are expected to increase further worldwide.<sup>6–8</sup> This threat is aggravated by the fact that there are currently no approved pharmacologic therapies for non-alcoholic steatohepatitis (NASH). Accurate and geographically-specific estimations of NASH prevalence by fibrosis stage are paramount for the design and implementation of public health measures and therapeutic strategies.

Nonetheless, the exact prevalence of NAFLD and for the different fibrosis stages of NASH remains unknown to date because previous calculations are subject to various problems. First, reports on NAFLD prevalence base their predictions on non-invasive diagnostic tests,<sup>9–13</sup> registry diagnostic codes<sup>14</sup> or on indirect extrapolations from basic metabolic demographics.<sup>15</sup> All these methods have suboptimal sensitivity and probably underestimate the real prevalence of NAFLD.<sup>2,16</sup> In recent years, Controlled Attenuation Parameter (CAP) by transient elastography (TE) has been proven more sensitive for the detection of steatosis than ultrasound or serum-based scores<sup>10,17–20</sup> but reports on NAFLD at the general population level using CAP are still scarce and small-scale.<sup>21</sup> Second, estimations of NASH at population level have been extrapolated from either small autopsy or living-donor series<sup>22</sup> or through back-calculations crossing population-scale estimates for NAFLD with non-contemporary NASH biopsy series<sup>23–25</sup> subject to selection and ascertainment biases, leading to overrepresentation of more advanced stages of NASH. An intermediate approach consists of the use non-invasive tests for estimations of liver fibrosis (with transient elastography and/or serum scores) as proxy for NASH in different population-based studies.<sup>26,27</sup> However, stratification of patients by fibrosis stage with these methods has been proven suboptimal and

### Lay summary

Non-alcoholic steatohepatitis (NASH) has become a major public health issue worldwide, but the exact prevalence in the general population of the different stages of liver fibrosis associated to NASH is largely unknown. In the present study, we merged data from a large general population-based dataset and a contemporary multicentric biopsy-proven NASH cohort to provide updated prevalence estimates for NASH fibrosis in Spain. These estimates might be leveraged for designing future interventions for NASH.

histological confirmation of fibrosis predictions is scarce.<sup>9,10</sup> Finally, the attribution of NAFLD causality in those fibrosis-based population studies has been indirect (basically based on comorbidities, without concurrent measurement of hepatic steatosis).

The aim of the present study was to provide an updated, accurate, real-life estimate of the prevalence of NASH-related fibrosis in Spain. For that purpose, we merged data from a large study on the use of TE for screening of liver disease in the general population of Spain with contemporary data from a multi-centre cohort of biopsy-proven NASH from real practice from our country.

## 2 | METHODS

### 2.1 | Aim and study design

This was an observational, retrospective, cross-sectional, population-based, epidemiological study. The main objective of the study was to provide updated estimates for the prevalence of NASH-related

fibrosis in the general population in Spain, with a special focus on those stages at higher risk of complications and that would be eventually amenable to receive pharmacologic therapy under the current regulatory framework, that is F2-4 fibrosis stages.

The general plan for the study (Figure 1) consisted of four steps:

- STEP 1: To estimate the prevalence and distribution of liver fibrosis through clinically relevant TE ranges in Spain's general population from a large population-based cohort (ETHON).
- STEP 2: To estimate the prevalence of NAFLD within the subset of patients with liver stiffness measurements (LSM)  $\geq 8$  kPa in the same cohort. For this estimation, we used the subcohort from Cantabria, which was the largest subcohort ( $N = 5090$ ) and contained 99.7% of all valid CAP measurements from the whole ETHON dataset. Patients with viral hepatitis (positive anti-HCV or HBsAg), high-risk alcohol consumption ( $\geq 15$  units/week) assessed by AUDIT test and those with the absence of steatosis defined as CAP  $< 250$  dB/m (except for patients with LSM  $\geq 20$  kPa in order to avoid "burn-out" NASH cirrhosis exclusion) were excluded. The proportion attributable to NAFLD was calculated as the ratio of the remaining patients after these exclusions over the total of patients with LSM  $\geq 8$  kPa (Figure 2).
- STEP 3: To describe the distribution of the different liver fibrosis stages in a Spanish multi-centre cohort of biopsy-proven NASH with paired TE (LSM and CAP) data, contemporary to the population-based cohort.
- STEP 4: To generate estimations of the real prevalence for the different NASH-related fibrosis stages for Spain's general population by crossing the estimated prevalence of NAFLD drawn from ETHON cohort with the probability of each specific stage of fibrosis observed in the biopsy-proven NASH cohort in patients with LSM  $\geq 8$  kPa.

As secondary outcome, using the same step by step approach detailed above, we aimed at describing prevalence estimates using




FIGURE 1 Study design and cohorts.

the LSM 9.1 kPa cut-off, which has been recently suggested as the most cost-efficient LSM threshold for theoretical population-level screening.<sup>28</sup>

The paper has been performed and written following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<sup>29</sup>


## 2.2 | Patients

The study integrates data from two large cohorts:

1. Population-based cohort (ETHON cohort). The PREVHEP-ETHON is a Spanish dataset composed of subjects aged 20–79 years selected from the general population of 18 primary care centres belonging to three university hospitals from 2015 to 2017. Participants were randomly selected and stratified by socioeconomic status, rural/urban setting and age. The geographical location of Santander, Madrid and Valencia (north, centre and east, respectively) determinates substantial differences in terms of weather, lifestyle and food habits, appropriately showing a real-life picture of Spain at population level. Thus, this cohort is considered representative of Spain's general population and has served as a reference for other observational, cross-sectional population-based studies,<sup>30</sup> even though the initial study was aimed to investigate the prevalence of HCV in the general population.<sup>31</sup>

This cohort was the basis for the estimation of TE values for the Spanish general population as well as for the estimation of the attributable causal weight of NAFLD within the range of LSM  $\geq 8$  kPa.

2. Biopsy-proven NASH cohort. This dataset was a cross-sectional, retrospective cohort of real clinical practice patients with biopsy-proven NASH from two hospitals from the ETHON cohort (Marqués de Valdecilla, Cantabria and Puerta de Hierro, Madrid) and three additional tertiary centres (Virgen del Rocío, Seville; Clínico Universitario, Valladolid; and Vall d'Hebron, Barcelona). These centres had been collecting data prospectively from NAFLD patients for several studies and for Spain's NAFLD National Registry (Hepamet).<sup>32</sup> Patient selection was based on what is estimated as current clinical practice in tertiary centres in Spain, where patients are referred to liver clinics based on a combination of altered liver function tests and/or finding of steatosis in liver ultrasound. Once in the clinics, patients with LSM  $< 8$  kPa are considered low risk and are less likely to undergo liver biopsy, and in patients with LSM  $\geq 8$  kPa liver biopsy is individually decided for disease staging and for inclusion consideration in clinical trials. For the present study, we only included consecutive patients with paired data from liver biopsy and TE within a  $< 12$ -month period obtained with Fibroscan devices equipped with M



**FIGURE 2** Flow chart for the calculation of the proportion attributable to non-alcoholic fatty liver disease (NAFLD) in the population-based cohort. CAP, controlled attenuation parameter; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; LSM, liver stiffness measurements; NAFLD, non-alcoholic fatty liver disease.

and XL probes, spanning from 2015 to 2020. Only liver samples clearly interpretable for the pathologists were included in the study.

The biopsy-proven cohort was used to translate TE estimations for the general Spanish population into histology-based estimations for NASH diagnosis and its different fibrosis stages.

### 2.3 | Procedures

TE measurements, liver biopsy and histological evaluation were performed according to current standards.<sup>33,34</sup> A detailed description of procedures is provided in Supplementary Material.

### 2.4 | Statistical analysis

For demographic extrapolations and comparisons with the Spanish general population, publicly available data from Instituto Nacional de Estadística (INE) were used. INE is a legally independent administrative institution which serves as main repository of demographic data for Spain, including key health indicators. Patients with non-valid LSM and those with LSM < 8 kPa from both cohorts will be

excluded from final analyses under the assumption that these patients would not be referred to tertiary centres to undergo liver biopsy in real clinical practice.

Categorical data are presented as number (percentage). Continuous data are presented as mean  $\pm$  standard deviation and median (interquartile range). A  $p < .05$  was considered statistically significant. Missing values were kept as missing, and no specific statistical procedures were used for imputations. Data were collected and edited using Microsoft Excel (version Microsoft Office Pro 2019). Statistical analyses were performed using PAWS Statistics (version 19.0; SPSS Inc., Hong Kong) software.

## 3 | RESULTS

### 3.1 | Patients characteristics from the population-based transient elastography cohort (ETHON cohort)

From the complete ETHON dataset of 12 246 individuals, 806 (6.6%) were excluded because of non-valid or indeterminate LSM.

For the 11 440 patients included in the analysis (Table 1) median age was 51 years, 58% were women and 88% were Caucasian. Median BMI was 26.1 kg/m<sup>2</sup> and 60% were either overweight or

**TABLE 1** Baseline characteristics of the patients from the general population (ETHON) cohort included in the analysis

General population cohort	N = 11440
Age, years	51 (42–60)
Male, n (%)	4792 (41.9)
Geographic subcohort, n (%)	
Cantabria	5090 (44)
Madrid	4088 (36)
Valencia	2262 (20)
Caucasian, n (%)	10058 (87.9)
Alcohol risk consumption, n (%)	442 (3.9)
Body mass index (BMI), kg/m <sup>2</sup>	26.1 (23.3–29.3)
Weight, n (%)	
Normal weight (<25 kg/m <sup>2</sup> )	3846 (40.4)
Overweight (≥25–<30 kg/m <sup>2</sup> )	3597 (37.8)
Obesity (≥30 kg/m <sup>2</sup> )	2075 (21.8)
Waist circumference, cm	90 (80–99)
Type 2 diabetes, n (%)	1540 (13.5)
Arterial hypertension, n (%)	5206 (53.6)
Dyslipidemia, n (%)	7418 (64.8)
Metabolic syndrome, n (%)	1764 (15.4)
Fasting glucose, (mg/dl)	86 (79–96)
Total cholesterol, (mg/dl)	197 (174–222)
HDL, (mg/dl)	57 (47–68)
LDL, (mg/dl)	113 (91–135)
Triglycerides, (mg/dl)	114 (78–172)
Creatinine, mg/dl	0.78 (0.67–0.91)
AST, (U/L)	22 (19–27)
ALT, (U/L)	20 (16–28)
ALP, (U/L)	68 (56–83)
GGT, (U/L)	20 (14–33)
Bilirubin, mg/dl	0.50 (0.40–0.65)
Albumin, g/dl	4.5 (4.3–4.6)
Platelets, x10E9/L	241 (205–282)
FIB-4 index	0.99 (0.72–1.36)
HBsAg positive, n (%)	90 (0.8)
Anti-HCV positive, n (%)	143 (1.3)
Liver stiffness, (kPa)	4.5 (3.6–5.6)
CAP, (dB/m) <sup>a</sup>	247 (209–293)

Note: Risk alcohol consumption: ≥15 units of alcohol/week. Hypertension: ≥140/90 mmHg or requiring treatment; type 2 diabetes: as a fasting plasma glucose ≥126 mg/dl or a non-fasting plasma glucose ≥180 mg/dl or requiring treatment.; dyslipidemia: serum triglycerides ≥150 mg/dl and/or total cholesterol >200 mg/dl, LDL >130 mg/dl, HDL <40 mg/dl in men and <50 mg/dl in women or requiring treatment. <sup>a</sup>Data from Cantabrian subcohort, N = 4714.

obese. Diabetes prevalence was 13.5% and 5206 patients (53.6%) had arterial hypertension. Almost 16% of the population met NCEP-ATP III criteria for metabolic syndrome.<sup>35</sup>

**TABLE 2** Prevalence of different ranges of LSM in the general population (ETHON) cohort

LSM ranges	Patients, n (%)	LSM ≥ 8 kPa, n (%)	LSM ≥ 10 kPa, n (%)
< 8 kPa	10797 (94.39)	643 (5.61)	299 (2.60)
8–10 kPa	344 (3.00)		
10–15 kPa	185 (1.62)		
15–20 kPa	36 (0.31)		
≥ 20 kPa	78 (0.68)		
Total	11440 (100)		

Abbreviation: LSM, liver stiffness measurements.

Subjects from Cantabria represented 44% of ETHON dataset. Within this subcohort, 23.4% were obese, 61.4% presented a BMI ≥ 25 kg/m<sup>2</sup> and 20% met metabolic syndrome criteria. Median LSM and CAP values from Cantabria were 4.4 kPa and 247 dB/m respectively. As shown, baseline features between the Cantabrian subcohort and the whole ETHON dataset were comparable.

Metabolic estimates from ETHON cohort were consistent with available data from Spain's general population, where 22.9%, 13.8% and 42.6% have been estimated to present obesity, diabetes and arterial hypertension respectively.<sup>36–39</sup>

### 3.2 | STEP 1: TE ranges

The first step consisted of the estimation of LSM ranges in the general population. Out of the 11440 individuals with reliable TE from ETHON cohort, 5.61% (95%CI 2.53–11.97) had LSM ≥ 8 kPa and 2.60% (95%CI 0.83–7.88) presented LSM ≥ 10 kPa (Table 2). Within the LSM ≥ 8 kPa subgroup, 53% (344/643\*100) of patients fell in the 8–10 kPa range.

### 3.3 | STEP 2: Estimation of the prevalence attributable to NAFLD within the LSM ≥ 8 kPa subcohort

The second step was to estimate the aetiologic relative weight of NAFLD within the LSM ≥ 8 kPa population. For this specific purpose, as mentioned above, we used the subcohort from Cantabria, which was the largest subcohort and contained 4714/4728 (99.7%) CAP measurements from the whole ETHON dataset.

As seen in Figure 2, the proportion attributable to NAFLD was 57.3% (109/190\*100), calculated as the ratio of the remaining subjects after exclusion of patients with viral hepatitis, high-risk alcohol consumption and those with the absence of steatosis assessed by CAP, over the total of patients with LSM ≥ 8 kPa and available CAP. Thus, the prevalence of individuals with LSM ≥ 8 kPa because of NAFLD in the general population was estimated to be 3.21% (5.61\*0.573).

### 3.4 | Patient characteristics from the biopsy-proven NASH cohort

The real clinical practice dataset was composed of 501 consecutive patients with histological confirmation of NASH and paired TE measurements from five tertiary hospitals in Spain. The main clinical features were usual in European NASH cohorts. Median age was 59 years and 57% were males. Median BMI was 32 kg/m<sup>2</sup>, 66% of patients had obesity and 44% type 2 diabetes. Median time between TE and liver biopsy was 2.29 months (IQR 1.12–4.41) and only 12.5% (63/501) of patients presented a time interval > 6 months between procedures. A detailed description of the baseline characteristics from the biopsy-proven NASH cohort and the comparison between both study cohorts are provided in Table S1.

### 3.5 | STEP 3: Description of the distribution of histological NASH-related fibrosis according to different LSM ranges

Among the 501 patients of the whole biopsy-proven NASH cohort, 112 patients had LSM < 8 kPa. Among these patients, 92 (82%) were F0-1, 15 presented F2, only 5 were F3 and no patients had cirrhosis on histology.




FIGURE 3 Distribution of liver fibrosis within increasing ranges of LSM in the biopsy-proven cohort of patients with non-alcoholic steatohepatitis (NASH)

Fibrosis	LSM ranges, n (%)				LSM ≥ 8 kPa	LSM ≥ 10 kPa
	8–10 kPa	10–15 kPa	15–20 kPa	≥ 20 kPa		
F0	25 (22.32)	23 (14.84)	3 (5.66)	1 (1.44)	52 (13.37)	27 (9.75)
F1	37 (33.04)	41 (26.45)	6 (11.32)	7 (10.15)	91 (23.39)	54 (19.49)
F2	28 (25.00)	28 (18.07)	7 (13.20)	7 (10.15)	70 (18.00)	42 (15.16)
F3	19 (16.96)	43 (27.74)	17 (32.08)	12 (17.39)	91 (23.39)	72 (26.00)
F4	3 (2.68)	20 (12.90)	20 (37.74)	42 (60.87)	85 (21.85)	82 (29.60)
Total	112 (100)	155 (100)	53 (100)	69 (100)	389 (100)	277 (100)

TABLE 3 Distribution of histological liver fibrosis according to LSM in the biopsy-proven NASH cohort

Abbreviation: LSM, liver stiffness measurements.

The distribution of fibrosis by different LSM ranges for the remaining 389 patients are shown in Figure 3 and Table 3. Among patients with LSM ≥ 8 kPa, 37% (143/389) had F0-1 and, for those patients with LSM ≥ 10 kPa, as much as 44% (123/277) did not show advanced fibrosis (F3-4) at histology. As seen, the proportion of patients with advanced fibrosis increased at each LSM interval, but even at the highest interval (LSM ≥ 20 kPa), there was a substantial proportion of patients without cirrhosis (39%).

Regarding liver biopsy quality parameters, median tissue length among patients with LSM ≥ 8 kPa was 23.0 mm (IQR 19.0–28.0), and only 5.1% of samples were fragmented into more than two pieces. Of note, the subset of patients within the highest LSM interval (≥ 20 kPa) showed similar quality data (21.5 mm median size -IQR 17.0–27.0- and 4.5% fragmentation respectively).

### 3.6 | STEP 4: Prevalence estimation of NASH-related fibrosis stages for Spain's general population (2015–2020)

The main study outcome was calculated by merging the main results from the two cohorts. The prevalence for each NASH-related fibrosis stage in Spain's general population was estimated by crossing the



estimated prevalence of NAFLD with LSM  $\geq$  8 kPa (3.21%) drawn from ETHON dataset with the different fibrosis stages probabilities observed in the biopsy-proven NASH cohort (detailed in Table 3—LSM  $\geq$  8 kPa column). The final calculations from our study are shown in Table 4 (i.e., prevalence of F2 fibrosis stage resulted in 0.58% = 3.21\*0.18). Finally, the estimated prevalence of NASH with significant fibrosis F2-4 in Spain was 2.03 (95% CI 0.56–7.05), 1.33 (95% CI 0.29–5.98) of the Spanish population aged 20–79 years presented NASH F2-3 and 0.70 (95% CI 0.10–4.95) was estimated to have NASH cirrhosis.

Additional estimations using the LSM  $\geq$  10 kPa threshold and alternative approximations to the proportion attributable to NAFLD using more or less conservative CAP thresholds (275 or 220dB/m, respectively) are provided in Tables S2–S5.

### 3.7 | Prevalence estimates with LSM 9.1 kPa threshold

The LSM  $\geq$  9.1 kPa threshold has been suggested as the most cost-effective cut-off for a theoretical TE-based screening programme of liver fibrosis in populations with lower prevalence of risk alcohol consumption, such as Spain.<sup>28</sup> Applying the same methodology used for the 8 kPa threshold we found that in ETHON cohort, prevalence of LSM  $\geq$  9.1 kPa was 3.36%. In our biopsy-proven cohort, 66.5% (223/335) of patients had significant fibrosis (F2-4) and 49.8% (167/335) presented advanced fibrosis (F3-4). The proportion attributable to NAFLD resulted in 55.2% of cases of all Spain's population with LSM  $\geq$  9.1 kPa, and thus 1.85% of Spain's population would be assumed to have NAFLD, with 1.10% estimated to have F2-4.

Of note, raising the threshold from 8.0 to 9.1 kPa in a hypothetical screening plan would represent a 39.9% relative reduction in the proportion of patients that would be targeted. However, according to our biopsy-proven cohort, in the subcohort of 54 patients with LSM 8–9.1 kPa, 9 (16.6%) had advanced fibrosis. The advantages and risks of using the 9.1 kPa threshold should be weighted in dedicated cost-effective studies.

## 4 | DISCUSSION

In the present study, we provide an updated estimation of the prevalence of NASH-related fibrosis in Spain's general population, by combining TE data from a large population-based screening cohort, and histological information from a contemporary multi-centre cohort of biopsy-proven NASH from Spain. We observed that 5.61% of the general population had LSM  $\geq$  8 kPa, 57.3% of which (3.21%) was attributable to NAFLD. By crossing these estimates with the corresponding probabilities for the different fibrosis stages by LSM intervals drawn from the biopsy-proven cohort, we estimated that the current prevalence of NASH with significant fibrosis in Spain was 2.03% (1.33% NASH F2-3 and 0.70% NASH cirrhosis).

The estimates on NASH with significant fibrosis from our study are lower than those provided in previous epidemiological reports from other European cohorts,<sup>28,40–42</sup> even though the prevalence of LSM  $\geq$  8 kPa in the ETHON population is almost the same. The most likely reason for these differences stems from the fact that fibrosis estimations in those studies were fundamentally TE-based (backed up by the absence of liver biopsies or a relatively small number of them) and, in the present study, TE estimations were back-tested against a large contemporary histological dataset, which clearly suggests that current TE-based definitions are overestimating the prevalence of fibrosis in NASH. In fact, 37% of the patients in our study with LSM  $\geq$  8 kPa did not have “significant fibrosis,” and 44% of patients with LSM  $\geq$  10 kPa did not have “advanced fibrosis” at histology. A recent paper,<sup>28</sup> integrating population-based TE data with histological data from 6 independent cohorts, with 6300 patients and 350 biopsies, showed an estimated prevalence of F2-4 in the general population (all aetiologies combined) of 3.9%. In our study, there were more than 12000 patients in the population-based cohort and more than 500 biopsies, which served at narrowing confidence intervals for the different degrees of fibrosis that could be expected at each TE interval, providing more precise references for the population-based estimates. As a practical consequence, we firmly believe that current TE-based definitions of “significant” and “advanced” fibrosis (LSM  $\geq$  8 kPa and 10 kPa, respectively) should be avoided, since they provide unrealistic overestimations of the actual prevalence of the corresponding fibrosis stages.

TABLE 4 Prevalence estimation of the different NASH fibrosis stages in Spain's general population

Fibrosis	Nash fibrosis prevalence (%)			
	LSM $\geq$ 8 kPa (95%CI)	Significant fibrosis (F2-F4)	Intermediate stages (F2-F3)	Cirrhosis (F4)
F0	0.43 (0.04–4.49)			
F1	0.75 (0.11–5.04)			
F2	0.58 (0.07–4.75)	2.03 (0.56–7.05)	1.33 (0.29–5.98)	
F3	0.75 (0.11–5.04)			
F4	0.70 (0.10–4.95)			0.70 (0.10–4.95)
Total	3.21 (1.13–8.75)			

Abbreviations: CI, confidence interval; LSM, liver stiffness measurements; NASH, non-alcoholic steatohepatitis.

The second reason for the different prevalence of NASH F2-4 is the more comprehensive attribution of aetiology made in our study, where we estimated that approximately 60% of patients with LSM  $\geq 8$  kPa from the general population had NAFLD. In the paper by Caballeria et al.,<sup>40</sup> attribution of NAFLD aetiology was made by exclusion of with viral hepatitis and patients with high-risk alcohol consumption, resulting in a remarkably high aetiologic weight of NAFLD (near 90%). On the other hand, in the other two large European studies,<sup>41,42</sup> NAFLD was suspected basically on clinical grounds, yielding a much lower estimated prevalence (32%–42% for the whole LSM spectrum). By contrast, to estimate the proportion attributable to NAFLD we added the use of CAP in nearly 5000 patients from a representative subcohort, enabling the extrapolation of the results to the whole dataset and, thus, to the general population. We believe that the combination of CAP along clinical and laboratory values in the present study likely provides the most accurate estimation for the attribution of aetiology in population-based studies to date.

The study has nonetheless some limitations that should be taken into account when interpreting the transferability of our results to real practice decisions. The main limitation is the risk of overestimation of the prevalence of F2-4 stages, as consequence of unavoidable referral and selection bias. It has been consistently shown that NASH prevalence is overestimated in tertiary settings.<sup>2</sup> Local initiatives for structured early detection and referral have been developed in recent years in the biopsy-proven cohort centres and may have helped at buffering that risk. However, the efficiency of systematic referral is still suboptimal, and thus mitigation of referral bias is probably modest. The risk of selection bias is also unavoidable in this kind of retrospective studies since decision for biopsy was not standardized and could have been influenced by other criteria different from LSM. However, it should be noted that current practice in all participating centres is quite homogenous and representative of what is done in daily clinical practice in Spain. In fact, the 2 main centres recruiting for the ETHON cohort were also part of the contemporary biopsy-proven cohort (Cantabria, Madrid). In any case, the ideal approach to minimize these biases would be the implementation of prospective large-scale screening programmes, with per-protocol liver biopsies above a pre-specified LSM threshold. Such a study is already ongoing (LiverScreen, H2020-EU ID 847989), but results of such large efforts will take long. Thus, until this sort of large-scale prospective data becomes available, the estimations provided in the present study remain as the most accurate approximations to the prevalence of NASH with significant fibrosis in a European population.

Other limitations should be considered. Biopsy reading was not centralized and could be subject of interobserver variability, although we believe this is a reflection of what should be expected in real-life situations. We acknowledge that the attribution of the relative weight of NAFLD as aetiology was imperfect. The choice of the CAP threshold was arbitrary, since there is no clear consensus in the literature and there are no clear published reports on the specificity and positive predictive values of CAP estimates for patients with higher LSM.<sup>10</sup> It can be also argued about the positive predictive value of 250dB/m CAP threshold to identify steatosis at

general population level. This issue can be partially mitigated in two ways. First, by adjusting CAP values according to influencing covariables, such as type-2 diabetes, BMI and liver aetiology.<sup>18</sup> Second, as provided in the present study, by generating alternative estimations using different CAP cutoffs with greater or lesser sensitivity (including the 275 dB/m threshold suggested in the latest clinical practice guideline).<sup>17</sup> Moreover, the estimation on the relative weight of NAFLD would require adjustment by the alcoholic liver disease burden in each country. There will be also patients with other liver aetiologies, although their reported frequencies in primary care series are very low (<2%) and should not distort significantly large-scale epidemiological estimations.<sup>43</sup> Finally, the ethnic background in our study is predominantly Caucasian, so extrapolation to populations with more diverse ethnicities should be done with caution.

In conclusion, our large-scale epidemiological study, merging population-based TE data with histological data from real-world practices, provides accurate and updated estimates of the current prevalence of NASH-related fibrosis in Spain, with a special focus on those stages that should be the target of early detection and referral policies to identify high-risk patients who will benefit more from the pharmacological therapies under development.

Until large-scale prospective epidemiological data with biopsy confirmation becomes available, our results could serve as reference points for both assessing the current burden of disease and for modelling changes in time, so health policies can be designed and adapted accordingly, and besides for dimensioning the therapeutic efforts that will be required as the time when we have effective treatments to treat NASH approaches.

#### ACKNOWLEDGEMENTS

The authors thank Intercept Pharma Spain and EY Spain, which helped at processing databases and providing descriptive analyses. Neither Intercept Pharma Spain nor EY Spain funded the study or had a role in the study design, interpretation of the data, writing or revision of the manuscript or the decision to submit the manuscript for publication. The authors also thank to LITMUS Consortium (Liver Investigation: Testing Marker Utility in Steatohepatitis LITMUS 777377 IMI-2 European Commission).

#### FUNDING INFORMATION

The work was independent of all funding. JRE is a PhD student at Universitat Autònoma de Barcelona, Spain. JC is a receptor of a grant of Fondo Investigaciones Sanitarias (FIS): PI18/01304. Immunomediated Nonalcoholic Steatohepatitis; prevalence and Characterization. INSTInCT.

#### CONFLICT OF INTEREST

JLC received consulting and lecture fees for Intercept, Echosens and Gilead Sciences. JMP received consulting, educational or research grants for Gilead, NovoNordisk, Novartis, Boehringer-Ingelheim, BMS, Pfizer, Accelerate, Astellas, ViiV, Janssen, MSD, Abbie. MRG received consulting fees from Alpha-sigma, Allergan, BMS, Boehringer-Ingelheim, Gilead, Intercept, Kaleido, MSD,



Pfizer, Prosciento, Shionogi, Sobi, Zydus and research Grants: Gilead, Intercept. SA changed affiliations after finalizing the manuscript and its submission to the journal. Boehringer Ingelheim did not fund the study and did not have any role in the study design, analysis or interpretation of the data, writing or revision of the manuscript or the decision to submit the manuscript for publication. Other potential conflicts of interest SA: consulting fees from Boehringer Ingelheim, Ferrer, Gilead, Intercept, IQVIA, Novartis, Pfizer; speaking fees from Allergan, Gilead, MSD and Novartis; travel expenses from Gilead, MSD, Janssen, Genfit, Bayer and Ferring; grant support from Gilead. JC received consulting fees from Gilead, Intercept, MSD, Abbie; grant support from Gilead, MSD.

## ETHICS STATEMENT

The study protocol was approved by Vall d'Hebron Ethics Committee for Clinical Research (PR[AG]655/2020) and conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

## PATIENT CONSENT FOR PUBLICATION

Not required.

## PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES

The material in this paper is original and does not come from other sources.

## ORCID

José L. Calleja  <https://orcid.org/0000-0002-2265-6591>

Jesús Rivera-Esteban  <https://orcid.org/0000-0003-4357-8817>

Marta Hernández-Conde  <https://orcid.org/0000-0002-7153-0493>

Juan M. Pericàs  <https://orcid.org/0000-0002-3645-3293>

Javier Ampuero  <https://orcid.org/0000-0002-8332-2122>

María T. Arias-Loste  <https://orcid.org/0000-0001-8864-3833>

Paula Iruzubieta  <https://orcid.org/0000-0001-9476-1801>

Manuel Romero-Gómez  <https://orcid.org/0000-0001-8494-8947>

Salvador Augustin  <https://orcid.org/0000-0002-3515-9033>

Javier Crespo  <https://orcid.org/0000-0001-8248-0172>

## REFERENCES

1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*. 2018;15(1):11-20.
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64(1):73-84.
3. Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. *Hepatology*. 2018;67(5):1726-1736.
4. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. *Gastroenterology*. 2020;158(7):1851-1864.
5. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on non-alcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology*. 2019;69(6):2672-2682.
6. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. *J Hepatol*. 2018;69(4):896-904.
7. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. *Clin Gastroenterol Hepatol*. 2019;17(4):748-755.e3.
8. Younossi ZM, Otgonsuren M, Henry L, et al. Association of non-alcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. *Hepatology*. 2015;62(6):1723-1730.
9. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. *J Hepatol*. 2018;68(2):305-315.
10. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2019;156(5):1264-1281.e4.
11. Younossi ZM, Noureddin M, Bernstein D, et al. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: expert panel recommendations. *Am J Gastroenterol*. 2021;116(2):254-262.
12. Castera L, Yuen Chan HL, Arrese M, et al. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol*. 2015;63(1):237-264.
13. Huber Y, Schulz A, Schmidtman I, et al. Prevalence and risk factors of advanced liver fibrosis in a population-based study in Germany. *Hepatol Commun*. 2022;6:1457-1466.
14. Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. *BMC Med*. 2018;16(1):130.
15. Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. *Diabetes Care*. 2015;38(9):1673-1679.
16. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther*. 2011;34(3):274-285.
17. Berzigotti A, Tsochatzis E, Bousier J, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *J Hepatol*. 2021;75(3):659-689.
18. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2019;156(6):1717-1730.
19. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. *J Hepatol*. 2017;66(5):1022-1030.
20. Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. *Liver Int*. 2015;35(9):2139-2146.
21. Fabrellas N, Hernández R, Graupera I, et al. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. *PLoS One*. 2018;13(9):e0200656.
22. Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. *J Hepatol*. 2007;47(2):239-244.
23. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic

- Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. *Clin Gastroenterol Hepatol*. 2015;13(4):643-654.e9.
24. Bedossa P, Patel K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. *Gastroenterology*. 2016;150(8):1811-1822.e4.
  25. Wong VW, Wong GLH, Choi PCL, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. *Gut*. 2010;59(7):969-974.
  26. Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. *Lancet Gastroenterol Hepatol*. 2017;2(4):288-297.
  27. Ginès P, Graupera I, Lammert F, et al. Screening for liver fibrosis in the general population: a call for action. *Lancet Gastroenterol Hepatol*. 2016;1(3):256-260.
  28. Serra-Burriel M, Graupera I, Torán P, et al. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. *J Hepatol*. 2019;71(6):1141-1151.
  29. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453-1457.
  30. Llop E, Iruzubieta P, Perelló C, et al. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. *United European Gastroenterol J*. 2021;9:1-10.
  31. Crespo J, Cuadrado A, Perelló C, et al. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. *J Viral Hepat*. 2020;27(4):360-370.
  32. Ampuero J, Aller R, Gallego-Durán R, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. *J Hepatol*. 2020;73(1):17-25.
  33. Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. *Hepatology*. 2013;57(3):1182-1191.
  34. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;41(6):1313-1321.
  35. Tobin J, Zazula T. National cholesterol education program (ncep). In: Anderson NB, ed. *Encyclopedia of health and behavior*. Vol 1. SAGE Publications, Inc; 2004:541-533.
  36. Sorriquer F, Goday A, Bosch-Comas A, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the di@bet.es study. *Diabetologia*. 2012;55:88-93.
  37. Gutiérrez-Fisac JL, Guallar-Castillón P, León-Muñoz LM, Graciani A, Banegas JR, Rodríguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. *Obes Rev*. 2012 Apr;13(4):388-392.
  38. Aranceta-Bartrina J, Pérez-Rodrigo C, Alberdi-Aresti G, Ramos-Carrera N, Lázaro-Masedo S. Prevalence of general obesity and abdominal obesity in the Spanish adult population (aged 25-64 years) 2014-2015: the ENPE study. *Rev Esp Cardiol (Engl Ed)*. 2016;69(6):579-587.
  39. Menendez E, Delgado E, Fernandez-Vega F, et al. Prevalence, diagnosis, treatment, and control of hypertension in Spain. Results of the di@bet.es study. *Rev Esp Cardiol (Engl Ed)*. 2016;69(6):572-578.
  40. Caballería L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. *Clin Gastroenterol Hepatol*. 2018;16(7):1138-1145.e5.
  41. Roulot D, Costes J-L, Buyck J-F, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. *Gut*. 2011;60(7):977-984.
  42. Koehler EM, Schouten JNL, Hansen BE, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. *J Hepatol*. 2012;57(6):1305-1311.
  43. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. *J Hepatol*. 2012;56(1):234-240.

#### SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

**How to cite this article:** Calleja JL, Rivera-Esteban J, Aller R, et al. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology. *Liver Int*. 2022;42:1783-1792. doi: [10.1111/liv.15323](https://doi.org/10.1111/liv.15323)